nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9784125.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-D55A1B20·Framework v5.0·Pipeline v0.4·Evaluated 01 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Cross-sectional study

Effect of Neoadjuvant Chemotherapy on Angiogenesis and Cell Proliferation of Breast Cancer Evaluated by Dynamic Enhanced Magnetic Resonance Imaging.

Chang et al.Chang, Lan·2022·BioMed research international·10.1155/2022/3156093 ↗

In brief

A clinically relevant breast cancer imaging study rendered uninterpretable by an unidentifiable comparator drug, internal reporting inconsistencies, and undefined biomarkers.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

BACKGROUND: Breast cancer is the uncontrolled proliferation of breast epithelial cells under the action of various carcinogenic factors. The evaluation of early efficacy of neoadjuvant chemotherapy for breast cancer is helpful to change the treatment plan in time. On this basis, dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) was used to evaluate the effects of neoadjuvant chemotherapy on angiogenesis and cell proliferation in breast cancer.

OBJECTIVE: To evaluate the effect of neoadjuvant chemotherapy on angiogenesis and cell proliferation of breast cancer by dynamic enhanced DCE-MRI.

METHOD: 80 breast cancer patients were divided into the routine chemotherapy group (3 cycles) and neoadjuvant chemotherapy groups (3 cycles) of 40 cases each from January 2018 to June 2021. Based on conventional imaging, DCE-MRI was performed with Intera Achieva 3.0 TMR superconducting MR scanner before and after treatment. The quantitative indexes, MRI parameters, cell proliferation expression, and DCE-MRI angiogenesis were compared between the two groups.

RESULT: The inhibition rate, Vepost, Ktranspre, ADC, Bax, Alexi, and Aurora in the neoadjuvant chemotherapy group were significantly higher than those in the conventional chemotherapy group (P < 0.05), while Kep, Ktrans, and Nek2 were significantly lower than those in the conventional chemotherapy group (P < 0.05). Vepre (cm3), Ktranspre (ml/min/100 cm3), and Ve had no significant difference (P > 0.05).

CONCLUSION: The quantitative parameters, MRI parameters, proliferation, and expression of DCE-MRI in breast cancer patients with different chemotherapy regimens are quite different. They can be applied to the diagnosis of neoadjuvant chemotherapy in breast cancer patients with angiogenesis and cell proliferation.

Strengths · Limitations

Strengths

#contribution

Clinically relevant research question addressed

The study targets a recognised unmet need: non-invasive evaluation of neoadjuvant chemotherapy response in breast cancer using DCE-MRI quantitative parameters, an active area of clinical and imaging research.

↳ Introduction §1

#methodological rigour

Multimodal assessment combining imaging and biomarkers

The study examines both DCE-MRI quantitative parameters (Ktrans, Kep, Ve, ADC) and protein expression markers (cell proliferation and angiogenesis), providing biological plausibility for the observed imaging differences.

↳ Results §3.1–3.4

#methodological rigour

Appropriate basic statistical methodology

The statistical approach includes Shapiro-Wilk normality testing with appropriate selection of parametric or non-parametric tests based on data distribution, demonstrating a basic level of analytical care.

↳ Methods §2.4

Limitations

#methodological rigour

Unidentifiable comparator drug renders comparison uninterpretable

The routine chemotherapy group received 'grace 7.5 mg/(m2·d),' which is not a recognised drug name and appears to be a translation artefact. The actual comparator treatment cannot be determined, making all between-group comparisons uninterpretable.

↳ Methods §2.3.1

#reporting

Material internal inconsistencies between abstract and results

The abstract reports 'Ktranspre' had no significant difference while Results §3.1 reports 'Ktranspost' was significantly higher — an apparent swap between pre- and post-treatment parameters. The Discussion contains temporal framing contradictions regarding when Ktrans and Kep changes occurred. These inconsistencies undermine confidence in the reported findings.

↳ Abstract; Results §3.1; Discussion §4

#methodological rigour

Contradictory data availability and absent research transparency

The Data Availability Statement claims 'No data were used to support this study,' which is factually impossible for a study reporting quantitative data from 80 patients. Ethics approval lacks an identifier, no conflict of interest disclosure is provided, and the randomised allocation to chemotherapy regimens lacks clinical trial registration.

↳ Data Availability Statement; Methods §2.1

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

The adjudicated scores reflect a paper that addresses a legitimate clinical question but is severely compromised in execution and reporting. The most decisive factor was the unidentifiable comparator drug ('grace,' §2.3.1), which renders all between-group comparisons — the paper's sole analytical framework — uninterpretable. This, combined with undefined biomarkers (ALEXI, Aurora, Nek2), the selective non-reporting of the pre-specified Vp parameter, and material abstract-results inconsistencies regarding which DCE-MRI parameters reached significance, collectively placed the Methodological Rigour score in the lower range. The reliability assessment was driven by both internal coherence concerns (reporting inconsistencies, translation artefacts, temporal framing contradictions) and research conduct concerns (contradictory data availability statement, unverifiable ethics approval, absent trial registration for what appears to be a randomised intervention). While the paper's structure is conventional and results are locatable, the comprehension barriers from machine-translation artefacts and undefined terminology limited the Reporting score. Impact potential remains low primarily because the study provides no diagnostic accuracy metrics, validation, or actionable thresholds that would be needed for clinical translation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.0±0.2

Contribution
2.2

The paper addresses a legitimate clinical question — DCE-MRI evaluation of neoadjuvant chemotherapy response in breast cancer — but does not articulate what it adds beyond existing literature on Ktrans and Kep changes with chemotherapy. The conclusion overstates the evidence by claiming diagnostic applicability from a small single-centre observational comparison.

Introduction §1; Conclusion; Abstract

can be applied to the diagnosis of neoadjuvant chemotherapy in breast cancer patients

Methodological Rigour
1.8

The comparator chemotherapy regimen uses an unidentifiable drug ('grace,' §2.3.1), rendering the core between-group comparison uninterpretable. Additional methodological gaps include no pharmacokinetic model specification for DCE-MRI analysis, no power calculation, no multiple comparisons correction, selective non-reporting of the pre-specified Vp parameter, and absent confounding control for tumour stage and receptor status. The Red reliability flag applies a cap at 2.0, but the merit-based score of 1.8 is already below this threshold.

Methods §2.3.1, §2.3.2, §2.4; Results §3.1–3.4

intravenous infusion of grace 7.5 mg/(m2·d) at weeks 1 to 2

Reporting
2.4

The paper follows a conventional IMRaD structure with clearly headed results sections, but comprehension is substantially impaired by machine-translation artefacts ('OV32 cm,' 'Scanner parameters:/TE wee'), undefined biomarker names (ALEXI, Aurora, Nek2), and a material inconsistency between the abstract and results regarding which DCE-MRI parameters showed significant differences.

Abstract vs. Results §3.1; Methods §2.3.2; Results §3.3

Scanner parameters:/TE wee as follows: 3.6 ms/1.1 ms, OV32 cm × 32 cm

Positioning
2.2

The paper cites relevant background on DCE-MRI and breast cancer but does not engage with the most pertinent prior studies (e.g., I-SPY trials, ACRIN 6657) or position its specific contribution against existing evidence. No limitations section is provided, and no reporting guideline is followed.

Introduction §1; Discussion §4

Reliability

Concerns4 of 4 checks


Internal CoherenceConcern

The paper contains material internal inconsistencies between the abstract and results sections regarding which DCE-MRI parameters showed significant differences (Ktranspre vs Ktranspost). The comparator chemotherapy drug is unidentifiable ('grace,' §2.3.1), multiple biomarkers are undefined (ALEXI, Aurora, Nek2), the Vp parameter defined in the methods never appears in results, and numerous machine-translation artefacts impede interpretation throughout.

Research ConductConcern

The Data Availability Statement ('No data were used to support this study') is factually impossible for a study analyzing 80 patients' MRI scans, blood parameters, and tissue samples. Ethics approval is declared without an IRB identifier or committee name. No conflict of interest statement, protocol registration, or reporting standard is provided. The described 'random number table' allocation to chemotherapy regimens constitutes an interventional study without clinical trial registration.

Flags: 1 declared / 5 total

Reference IntegrityClean

All 34 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2023-06-21. See notice: 10.1155/2023/9784125.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Breast cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceConsolidates
BeneficiariesLarge
CitationsFWCI 0.6
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on one single-centre comparison of 80 patients, shown working once without independent replication.

From the paper
“which can be applied to the diagnosis of angiogenesis and cell proliferation in patients with neoadjuvant chemotherapy breast cancer”

The conclusion names a diagnostic use for these findings but does not specify which professionals, services, or settings would act on them.

Pathway

Radiologists and oncologists could use DCE-MRI quantitative parameters to monitor early response to neoadjuvant chemotherapy and adjust breast cancer treatment plans.

Barrier

Findings come from a single 80-patient centre without external validation or standardised parameter thresholds, so independent multi-centre confirmation is required.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network

    Markiewicz, Thompson, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →